Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer

by W. Douglas Fairlie, Erinna F. Lee
Published 2021-03-01

The Structural Biology of Bcl-x_L

by Erinna F. Lee, W. Douglas Fairlie
Published 2019-05-01

STRUCTURAL BIOLOGY OF THE INTRINSIC CELL DEATH PATHWAY: WHAT DO WE KNOW AND WHAT IS MISSING?

by Erinna F. Lee, W. Douglas Fairlie
Published 2012-04-01

BECLIN1: Protein Structure, Function and Regulation

by Sharon Tran, W. Douglas Fairlie, Erinna F. Lee
Published 2021-06-01

A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma

by Surein Arulananda, Megan O’Brien, Marco Evangelista, Laura J. Jenkins, Ashleigh R. Poh, Marzena Walkiewicz, Trishe Leong, John M. Mariadason, Jonathan Cebon, Srividya B. Balachander, Justin R. Cidado, Erinna F. Lee, Thomas John, Walter D. Fairlie
Published 2021-05-01

Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma

by Surein Arulananda, Megan O’Brien, Marco Evangelista, Tiffany J. Harris, Nikita S. Steinohrt, Laura J. Jenkins, Marzena Walkiewicz, Robert J. J. O’Donoghue, Ashleigh R. Poh, Bibhusal Thapa, David S. Williams, Trishe Leong, John M. Mariadason, Xia Li, Jonathan Cebon, Erinna F. Lee, Thomas John, W. Douglas Fairlie
Published 2021-06-01

Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer

by Stephanie Berger, Erik Procko, Daciana Margineantu, Erinna F Lee, Betty W Shen, Alex Zelter, Daniel-Adriano Silva, Kusum Chawla, Marco J Herold, Jean-Marc Garnier, Richard Johnson, Michael J MacCoss, Guillaume Lessene, Trisha N Davis, Patrick S Stayton, Barry L Stoddard, W Douglas Fairlie, David M Hockenbery, David Baker
Published 2016-11-01